Source-grounded facts extracted from Immunovant, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Immunovant, Inc. reported fourth quarter and fiscal year ended March 31, 2026 results: net income $147.9 million ($0.73 per common share), EPS ($0.73 per common share).
“Net loss was $147.9 million ($0.73 per common share) for the three months ended March 31, 2026, compared to $106.4 million ($0.64 per common share) for the three months ended March 31, 2025.”
Jacob Bauer was appointed as Member of Board of Directors at Immunovant, Inc..
“the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky”
Robert Susman was appointed as Member of Board of Directors at Immunovant, Inc..
“the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky”
George Migausky resigned as Member of Board of Directors at Immunovant, Inc..
“On April 18, 2025, George Migausky, a member of Immunovant’s Board and Chair of the Audit Committee of the Board (the “Audit Committee”), resigned from the Board and the Audit Committee, effective immediately.”
Renee Barnett departed as Chief Financial Officer at Immunovant, Inc..
“Also effective April 20, 2025, Renee Barnett ceased serving as the Chief Financial Officer (including the principal financial officer and principal accounting officer) of the Company.”
Peter Salzmann retired as Member of Board of Directors at Immunovant, Inc..
“and as a member of the Company’s Board of Directors (the “Board”), effective April 18, 2025.”
Peter Salzmann retired as Chief Executive Officer at Immunovant, Inc..
“Peter Salzmann, M.D. retired from his roles as the Chief Executive Officer and principal executive officer of Immunovant, Inc. (the "Company" or "Immunovant"), effective April 20, 2025”
Immunovant, Inc. reported the fiscal nine months ended December 31, 2023 results: net income Net loss was $184.0 million ($1.36 per common share), EPS $1.36 per common share.
“Net loss was $184.0 million ($1.36 per common share) for the nine months ended December 31, 2023, compared to $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022.”
Immunovant, Inc. reported the fiscal third quarter ended December 31, 2023 results: net income Net loss was $51.4 million ($0.36 per common share), EPS $0.36 per common share.
“Net loss was $51.4 million ($0.36 per common share) for the three months ended December 31, 2023, compared to $63.2 million ($0.49 per common share) for the three months ended December 31, 2022.”
Immunovant, Inc. reported financial results for fiscal second quarter and six months ended September 30, 2023.
“On November 9, 2023, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2023.”
Immunovant, Inc. entered into Purchase Agreement with Roivant Sciences, Ltd. valued at approximately $170,000,000 (effective 2023-09-26).
“On September 26, 2023, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Roivant Sciences, Ltd. (“RSL”).”
Immunovant, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters valued at approximately $280,060,000 (effective 2023-09-27).
“On September 27, 2023, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives (the “Representatives”) of the underwriters listed on Schedule A thereto, relating to the issuance and sale in an underwritten public offering (the “Public Offering”) by the Company of 7,370,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a public offering price of $38.00 per share.”
Immunovant, Inc. shareholders approved Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant’s Named Executive Officers at the 2023-08-21 meeting.
“Proposal 3- Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant’s Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 115,397,185 825,452 8,173 4,982,266”
Immunovant, Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-08-21 meeting.
“Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant’s independent registered public accounting firm for the year ending March 31, 2024, by the following votes: Votes For Votes Against Votes Abstain 121,206,460 5,261 1,355”
Immunovant, Inc. shareholders approved Election of Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky as directors at the 2023-08-21 meeting.
“Proposal 1 – Election of Directors Peter Salzmann, M.D., M.B.A., Douglas Hughes and George Migausky were each elected to serve as a member of Immunovant’s Board of Directors, or the Board, until the 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Peter Salzmann, M.D., M.B.A. 98,532,525 17,698,285 4,982,266 Douglas Hughes 96,590,902 19,639,908 4,982,266 George Migausky 96,550,901 19,679,909 4,982,266”
Immunovant, Inc. reported fiscal first quarter ended June 30, 2023 results: net income Net loss was $73.9 million ($0.57 per common share), EPS $0.57 per common share.
“Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023”
Immunovant, Inc. reported the fiscal year ended March 31, 2023 results: net income $211.0 million, EPS $1.71 per common share.
“Net loss was $211.0 million ($1.71 per common share) for the fiscal year ended March 31, 2023”
Immunovant, Inc. reported the three months ended March 31, 2023 results: net income $59.4 million, EPS $0.46 per common share.
“Net loss was $59.4 million ($0.46 per common share) for the three months ended March 31, 2023”
Immunovant, Inc. reported fiscal nine months ended December 31, 2022 results: net income $151.5 million ($1.26 per common share), EPS ($1.26 per common share).
“Net loss was $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022”
Immunovant, Inc. reported fiscal third quarter ended December 31, 2022 results: net income $63.2 million ($0.49 per common share), EPS ($0.49 per common share).
“Net loss was $63.2 million ($0.49 per common share) for the three months ended December 31, 2022”
Immunovant, Inc. reported its fiscal second quarter and six months ended September 30, 2022 results: net income Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022, EPS $0.76 per common share.
“Net loss was $47.9 million ($0.41 per common share) for the three months ended September 30, 2022”
Eric Venker was elected as Director at Immunovant, Inc..
“Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant”
Atul Pande was elected as Director at Immunovant, Inc..
“Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant”
Andrew Fromkin was elected as Director at Immunovant, Inc..
“Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant”
Frank M. Torti was elected as Director at Immunovant, Inc..
“Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant”
Renee Barnett was appointed as Chief Financial Officer at Immunovant, Inc..
“On September 14, 2021, Renee Barnett was appointed the Chief Financial Officer of Immunovant, Inc. effective October 4, 2021.”
Dr. Frank M. Torti was appointed as Executive Chairperson at Immunovant, Inc..
“Effective August 2, 2021, Dr. Frank M. Torti, age 42, Immunovant’s current Chairperson, was appointed Executive Chairperson.”
Pamela Yanchik Connealy resigned as Chief Financial Officer at Immunovant, Inc..
“On July 7, 2021, Pamela Yanchik Connealy, the Chief Financial Officer of Immunovant, Inc., resigned from Immunovant, such resignation to be effective on July 16, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.